Table 1

Safety-related eligibility criteria for adult CAR T-cell clinical trials at the NCI

Clinical categoryEligibility criteria
Patient characteristics ECOG performance status 0-1; and 
Not pregnant or breastfeeding 
Pulmonary No active obstructive or restrictive pulmonary disease 
Hematologic* Hemoglobin ≥8.0 g/dL; 
Platelets ≥45 000/mm3 without transfusion support; 
ANC ≥1000/mm3 without growth factor support; 
No active hemolytic anemia; and 
No active coagulopathy 
Other end organ function Serum creatinine ≤1.4 mg/dL; 
Total bilirubin ≤2.0 mg/dL; 
Serum AST and ALT ≤3 times the institutional upper limit of normal unless liver involvement by malignancy is demonstrated; 
No active seizure disorder; and 
No current CNS involvement with malignancy 
Infectious disease No history or serologic evidence of HIV, hepatitis B, or hepatitis C; and 
No active uncontrolled systemic infection 
Immunologic No active autoimmune disease; and 
No history of primary immunodeficiency 
Clinical categoryEligibility criteria
Patient characteristics ECOG performance status 0-1; and 
Not pregnant or breastfeeding 
Pulmonary No active obstructive or restrictive pulmonary disease 
Hematologic* Hemoglobin ≥8.0 g/dL; 
Platelets ≥45 000/mm3 without transfusion support; 
ANC ≥1000/mm3 without growth factor support; 
No active hemolytic anemia; and 
No active coagulopathy 
Other end organ function Serum creatinine ≤1.4 mg/dL; 
Total bilirubin ≤2.0 mg/dL; 
Serum AST and ALT ≤3 times the institutional upper limit of normal unless liver involvement by malignancy is demonstrated; 
No active seizure disorder; and 
No current CNS involvement with malignancy 
Infectious disease No history or serologic evidence of HIV, hepatitis B, or hepatitis C; and 
No active uncontrolled systemic infection 
Immunologic No active autoimmune disease; and 
No history of primary immunodeficiency 

ALT, alanine aminotransferase; ANC, absolute neutrophil count; AST, aspartate aminotransferase; ECOG, Eastern Cooperative Oncology Group.

*

Hematologic criteria must be met for enrollment regardless of bone marrow involvement with malignancy.

or Create an Account

Close Modal
Close Modal